Opyl has partnered with L39 Capital to launch the AI-Powered Biotech Investment Fund, which will focus on investee companies carrying out active phase II or phase III clinical trials. The robots ...

By Kim Hyelin The human immune system, gene editors designed by artificial intelligence (AI), living biological robots and ...

Opyl is parterning with L39 Capital to launch a fund using robots to select stocks. Opyl (ASX:OPL) reckons the answer is no-one and is about to prove it with the world’s first AI-driven biotech ...

New investments in biotechnology, industrial robots, hyperscale data centers, and more on horizon, with support for tech ...